ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2545

Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis

Samina A. Turk1, Dirkjan van Schaardenburg1,2, Linda A. Rasch3, Véronique Lugt1, Willem F. Lems1,3, Mike T. Nurmohamed1,4 and Lilian van Tuyl3, 1Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, 2Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 3Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 4Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: Early Rheumatoid Arthritis, patient outcomes and remission

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Disease Activity Score (DAS) and the European League Against Rheumatism (EULAR) response criteria are commonly used to describe disease activity in Rheumatoid Arthritis (RA) patients(1). This study investigates the relationship between remission perceived by physicians versus patients according to the EULAR response criteria.

Methods: Consecutive RA patients with high disease activity and/or unfavourable prognostic factors and no prior treatment were investigated. Patients were treated with methotrexate and prednisolone (week 1: 30 mg, week 2: 20  mg, week 3: 15 mg, week 4-8: 10 mg, week 9-12: 7,5 mg). After 12 weeks of treatment the EULAR response was determined, according to the DAS44. Physician perceived remission was defined as a physician global assessment ≤ 20  on a visual analogue scale (VAS), phrased: “How active do you think the rheumatoid arthritis of your patient is today?”. For patient perceived remission the following question was phrased: “Would you say that, at this moment, your disease activity is as good as gone? (yes/no)(2).

Results: In 75 early RA patients the mean (SD) DAS44 decreased from 3.4 (1.2) to 1.5 (1.0) after 12 weeks of therapy. The number of good, moderate and none EULAR responders were 54 (72%), 14 (19%) and 7 (9%) respectively. After 12 weeks 72% of the physicians perceived remission as well as 72% of the patients, see figure 1. The spearman’s rho test showed significant correlations between the EULAR response versus perception of physicians, the EULAR response versus the perception of patients and the perception of patients versus physicians, respectively r=0.645 (p<0.001), r=0.393 (p=0.001) and r=0.267 (p=0.036). In 61% of the good EULAR responders the physician as well as the patient perceived remission, but in 33% only the physician perceived remission, see figure 2. Patients who did not perceive remission had a significantly different mean (SD) DAS44 of 1.4 (0.5) compared to 0.9 (0.5) in the patients who perceived remission (p=0.001). The difference in DAS44 is caused by tender joint count (TJC) and patient global (PG) but not by swollen joint count or erythrocyte sedimentation rate.

Conclusion: There is a significant correlation between EULAR response and both physicians and patients perceived remission in early RA patients. However, 33% of the patients with a good EULAR response and physician perceived remission, perceive no remission themselves. These patients had a significantly higher DAS44, caused by a higher TJC and PG. Literature:

1)       Van Riel et al. Clin Exp Rheumatol 2005 Sep;23:S93-99

2)       Van Tuyl LH et al.,  Ann Rheum Dis 2015 Jun;74(6):1004-10.  

   


Disclosure: S. A. Turk, None; D. van Schaardenburg, None; L. A. Rasch, None; V. Lugt, None; W. F. Lems, Pfizer Inc, 2,BMS, 8,Abbvie, 8,Lilly, 8,Pfizer Inc, 8,Roche Pharmaceuticals, 8; M. T. Nurmohamed, None; L. van Tuyl, None.

To cite this abstract in AMA style:

Turk SA, van Schaardenburg D, Rasch LA, Lugt V, Lems WF, Nurmohamed MT, van Tuyl L. Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/physicians-but-not-patients-agree-that-eular-good-response-indicates-remission-after-12-weeks-treatment-of-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2016

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physicians-but-not-patients-agree-that-eular-good-response-indicates-remission-after-12-weeks-treatment-of-early-rheumatoid-arthritis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology